Corcept Therapeutics Incorporated (CORT)
NASDAQ
Market Cap
$3.29B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
546 of 809
Rank in Industry
299 of 445
Largest Insider Buys in Sector
CORT Stock Price History Chart
CORT Stock Performance
About Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. The company is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California.
Insider Activity of Corcept Therapeutics Incorporated
Over the last 12 months, insiders at Corcept Therapeutics Incorporated have bought $0 and sold $12.01M worth of Corcept Therapeutics Incorporated stock.
On average, over the past 5 years, insiders at Corcept Therapeutics Incorporated have bought $4.67M and sold $7.87M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 150,000 shares for transaction amount of $3.23M was made by BAKER G LEONARD JR (director) on 2021‑06‑11.
List of Insider Buy and Sell Transactions, Corcept Therapeutics Incorporated
| 2024-06-03 | Sale | Lyon Joseph Douglas | See Remarks | 5,000 0.0046% | $30.18 | $150,916 | +0.67% | |
| 2024-06-03 | Sale | Guyer William | Chief Development Officer | 10,000 0.0098% | $32.00 | $320,000 | +0.67% | |
| 2024-06-03 | Sale | Swisher Daniel N JR | director | 2,200 0.002% | $30.21 | $66,462 | +0.67% | |
| 2024-05-28 | Sale | Robb Gary Charles | Chief Business Officer | 11,000 0.0102% | $30.39 | $334,294 | -0.98% | |
| 2024-05-28 | Sale | Guyer William | Chief Development Officer | 30,000 0.0292% | $32.00 | $960,000 | -0.98% | |
| 2024-05-13 | Sale | Maduck Sean | See Remarks | 50,000 0.0488% | $28.00 | $1.4M | +9.44% | |
| 2024-05-09 | Sale | Lyon Joseph Douglas | See Remarks | 7,227 0.0068% | $26.00 | $187,902 | +12.85% | |
| 2024-05-02 | Sale | Lyon Joseph Douglas | See Remarks | 10,830 0.0109% | $26.00 | $281,580 | +15.42% | |
| 2024-05-01 | Sale | Swisher Daniel N JR | director | 2,200 0.0021% | $23.09 | $50,798 | +20.94% | |
| 2024-04-04 | Sale | Lyon Joseph Douglas | See Remarks | 5,443 0.0055% | $26.00 | $141,524 | +9.92% | |
| 2024-04-01 | Sale | Lyon Joseph Douglas | See Remarks | 500 0.0005% | $26.01 | $13,004 | +6.92% | |
| 2024-04-01 | Sale | Swisher Daniel N JR | director | 2,200 0.0021% | $25.30 | $55,660 | +6.92% | |
| 2024-03-27 | Sale | Maduck Sean | See Remarks | 25,953 0.0248% | $25.01 | $649,025 | +6.91% | |
| 2024-03-18 | Sale | Maduck Sean | See Remarks | 17,219 0.0171% | $25.00 | $430,475 | +5.06% | |
| 2024-03-01 | Sale | Swisher Daniel N JR | director | 2,200 0.0021% | $23.59 | $51,898 | +4.74% | |
| 2024-02-16 | Sale | Maduck Sean | See Remarks | 27,068 0.03% | $25.97 | $702,905 | +8.78% | |
| 2024-02-16 | Sale | Lyon Joseph Douglas | Chief Accounting Officer | 1,000 0.0011% | $26.00 | $26,000 | +8.78% | |
| 2024-02-15 | Sale | Maduck Sean | See Remarks | 4,760 0.0048% | $25.00 | $119,000 | +0.82% | |
| 2024-02-01 | Sale | Swisher Daniel N JR | director | 2,200 0.0022% | $22.00 | $48,400 | +13.08% | |
| 2024-01-02 | Sale | Swisher Daniel N JR | director | 2,200 0.002% | $22.11 | $48,642 | +0.88% |
Insider Historical Profitability
18.52%
| Maduck Sean | See Remarks | 85222 0.0711% | $31.60 | 0 | 26 | |
| Hunt Hazel | Chief Scientific Officer | 73146 0.071% | $31.60 | 0 | 1 | |
| Robb Gary Charles | Chief Business Officer | 20203 0.0208% | $31.60 | 1 | 22 | +72.23% |
| MAHONEY DAVID L | director | 11297 0.011% | $31.60 | 12 | 9 | +42.33% |
| Guyer William | Chief Development Officer | 6039 0.0064% | $31.60 | 0 | 3 | |
| Lyon Joseph Douglas | Chief Accounting Officer | 7314 0.0057% | $31.60 | 0 | 20 | |
| Swisher Daniel N JR | director | 0 0% | $31.60 | 0 | 20 | |
| PENHOET EDWARD | 5484063 5.3201% | $31.60 | 1 | 0 | +78.79% | |
| ALTA BIOPHARMA PARTNERS II LP | 10 percent owner | 5484063 5.3201% | $31.60 | 2 | 0 | +16.86% |
| SUTTER HILL VENTURES | 10 percent owner | 5217464 5.0615% | $31.60 | 6 | 0 | +59.94% |
| MARDUEL ALIX | 10 percent owner | 5043299 4.8926% | $31.60 | 3 | 0 | +59.16% |
| GAITHER JAMES C | 10 percent owner | 4338742 4.2091% | $31.60 | 5 | 0 | +56.16% |
| Speiser Michael L | 10 percent owner | 4338742 4.2091% | $31.60 | 1 | 0 | +13% |
| BAKER G LEONARD JR | director | 3308303 3.2094% | $31.60 | 40 | 5 | +21.66% |
| BELANOFF JOSEPH K | Chief Executive Officer | 2538218 2.4624% | $31.60 | 0 | 101 | |
| SCHATZBERG ALAN F | director, 10 percent owner | 2438749 2.3659% | $31.60 | 1 | 1 | +197.78% |
| SINGER DAVID B | director | 731667 0.7098% | $31.60 | 0 | 2 | |
| YOUNGER WILLIAM H JR | 10 percent owner | 575066 0.5579% | $31.60 | 6 | 0 | +59.94% |
| COXE TENCH | 10 percent owner | 360048 0.3493% | $31.60 | 6 | 0 | +59.94% |
| ANDERSON DAVID L | 10 percent owner | 289747 0.2811% | $31.60 | 6 | 0 | +59.94% |
| COOK JOSEPH C JR | director | 241521 0.2343% | $31.60 | 18 | 1 | +61.71% |
| ANDERSSON ALLEN | director | 209694 0.2034% | $31.60 | 46 | 8 | <0.0001% |
| Paperboy Ventures, LLC | director | 209694 0.2034% | $31.60 | 46 | 6 | <0.0001% |
| Longitude Venture Partners L.P. | 10 percent owner | 180103 0.1747% | $31.60 | 3 | 16 | +27.2% |
| BRADBURY DANIEL | director | 177925 0.1726% | $31.60 | 4 | 12 | +44.97% |
| BIRD JEFFREY W | 10 percent owner | 126252 0.1225% | $31.60 | 6 | 0 | +59.94% |
| WHITE JAMES N | 10 percent owner | 121117 0.1175% | $31.60 | 6 | 0 | +59.94% |
| ENRIGHT PATRICK G | director | 114675 0.1112% | $31.60 | 3 | 23 | +27.2% |
| SANDS GREGORY P | 10 percent owner | 109913 0.1066% | $31.60 | 7 | 1 | +49.02% |
| Harper James A | director | 57900 0.0562% | $31.60 | 6 | 0 | +81.34% |
| SWEET DAVID E | 10 percent owner | 18480 0.0179% | $31.60 | 6 | 0 | +59.94% |
| SHEEHAN ANDREW T | 10 percent owner | 18325 0.0178% | $31.60 | 4 | 0 | +17.87% |
| GALA RENEE D | director | 10000 0.0097% | $31.60 | 2 | 0 | <0.0001% |
| TURNER JOSEPH L | director | 10000 0.0097% | $31.60 | 2 | 0 | <0.0001% |
| KURLAND FRED | Chief Financial Officer | 7500 0.0073% | $31.60 | 2 | 0 | +11.49% |
| Lo Steven | VP Commercial Operations | 0 0% | $31.60 | 0 | 4 | |
| ROE ROBERT L | President and Secretary | 0 0% | $31.60 | 0 | 73 | |
| WILSON JAMES N | director | 0 0% | $31.60 | 4 | 28 | +50.46% |
| FISHMAN ROBERT S | Chief Medical Officer | 0 0% | $31.60 | 0 | 12 |
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
| BlackRock | $423.85M | 16.16 | 16.83M | +2.55% | +$10.54M | 0.01 | |
| The Vanguard Group | $240.96M | 9.19 | 9.57M | +0.3% | +$711,617.50 | 0.01 | |
| Ingalls Snyder Llc | $209.16M | 7.98 | 8.3M | -0.58% | -$1.23M | 9.78 | |
| Renaissance Technologies | $179.31M | 6.84 | 7.12M | +5.84% | +$9.89M | 0.29 | |
| Parallel Advisors, LLC | $96.12M | 3.67 | 3.82M | +1.26% | +$1.19M | 2.62 | |
| State Street | $90.07M | 3.43 | 3.58M | +5.55% | +$4.74M | <0.01 | |
| Dimensional Fund Advisors | $64.68M | 2.47 | 2.57M | +11.14% | +$6.48M | 0.02 | |
| Novo Holdings A/S | $60.74M | 2.32 | 2.41M | 0% | +$0 | 4.24 | |
| Geode Capital Management | $54.36M | 2.07 | 2.16M | +5.48% | +$2.83M | 0.01 | |
| First Trust | $46.32M | 1.77 | 1.84M | +1,150.82% | +$42.62M | 0.05 | |
| Boston Trust Walden Corp | $46.23M | 1.76 | 1.84M | -0.64% | -$298,022.89 | 0.33 | |
| Arrowstreet Capital, Limited Partnership | $42.49M | 1.62 | 1.69M | +53.18% | +$14.75M | 0.04 | |
| Morgan Stanley | $38.11M | 1.45 | 1.51M | +16.74% | +$5.46M | <0.01 | |
| Man Group Plc | $37.76M | 1.44 | 1.5M | +81.44% | +$16.95M | 0.09 | |
| D. E. Shaw & Co. | $28.54M | 1.09 | 1.13M | -31.69% | -$13.24M | 0.04 | |
| Voloridge Investment Management, LLC | $26.03M | 0.99 | 1.03M | +88.79% | +$12.24M | 0.06 | |
| Northern Trust | $24.27M | 0.93 | 963,443 | -11.73% | -$3.23M | <0.01 | |
| Charles Schwab | $23.51M | 0.9 | 933,461 | +3.67% | +$831,698.21 | 0.01 | |
| Fidelity Investments | $21.47M | 0.82 | 852,345 | +19.81% | +$3.55M | <0.01 | |
| Two Sigma | $20.62M | 0.79 | 818,475 | +71.39% | +$8.59M | 0.04 | |
| Invesco | $19.4M | 0.74 | 770,280 | +13.79% | +$2.35M | <0.01 | |
| Two Sigma Advisers LP | $19.15M | 0.73 | 760,200 | +41.72% | +$5.64M | 0.03 | |
| Jupiter Fund Management | $18.75M | 0.72 | 744,469 | +1,148.98% | +$17.25M | 0.05 | |
| Jacobs Levy Equity Management | $18.43M | 0.7 | 731,468 | New | +$18.43M | 0.08 | |
| BNY Mellon | $18.24M | 0.7 | 724,022 | -6.31% | -$1.23M | <0.01 | |
| Cerity Partners | $17.02M | 0.65 | 675,843 | +812.48% | +$15.16M | 0.05 | |
| Bank of America | $16.96M | 0.65 | 673,354 | +134.29% | +$9.72M | <0.01 | |
| ClearBridge Investments | $14.67M | 0.56 | 582,355 | New | +$14.67M | 0.01 | |
| Millennium Management LLC | $13.93M | 0.53 | 553,007 | -19.86% | -$3.45M | 0.01 | |
| Connor Clark & Lunn Investment Management Ltd | $13.66M | 0.52 | 542,178 | +50.1% | +$4.56M | 0.03 | |
| Goldman Sachs | $10.95M | 0.42 | 434,722 | -18.4% | -$2.47M | <0.01 | |
| Burney Wealth Management | $10.87M | 0.42 | 431,638 | +2.96% | +$312,406.11 | 0.46 | |
| Cubist Systematic Strategies | $8.85M | 0.34 | 351,374 | +51.01% | +$2.99M | 0.08 | |
| ROYCE & ASSOCIATES INC | $8.47M | 0.32 | 336,272 | +0.06% | +$4,962.43 | 0.08 | |
| Cambridge Investment Research Advisors Inc | $8.17M | 0.31 | 324,271 | +2,922.66% | +$7.9M | 0.03 | |
| Ameriprise Financial | $7.38M | 0.28 | 292,900 | +6.57% | +$455,151.96 | <0.01 | |
| S&T Bank | $7.32M | 0.28 | 290,487 | -9.46% | -$764,452.91 | 1.4 | |
| Barclays | $6.93M | 0.26 | 275,244 | +51.61% | +$2.36M | <0.01 | |
| Janus Henderson | $6.68M | 0.26 | 265,049 | +482.55% | +$5.53M | <0.01 | |
| Citadel Advisors LLC | $6.66M | 0.25 | 264,309 | -40.2% | -$4.48M | <0.01 | |
| AQR Capital | $6.51M | 0.25 | 258,408 | +182.62% | +$4.21M | 0.01 | |
| Legal & General | $6.25M | 0.24 | 248,278 | -1.27% | -$80,230.16 | <0.01 | |
| Franklin Templeton Investments | $6.18M | 0.24 | 245,462 | +7.86% | +$450,321.65 | <0.01 | |
| Acadian Asset Management | $5.94M | 0.23 | 236,199 | -13.73% | -$946,187.14 | 0.02 | |
| Nuveen | $5.52M | 0.21 | 219,037 | -16.84% | -$1.12M | <0.01 | |
| RhumbLine Advisers | $5.21M | 0.2 | 206,744 | -2.61% | -$139,778.66 | 0.01 | |
| Engineers Gate Manager Lp | $5.21M | 0.2 | 206,751 | +1,744.34% | +$4.93M | 0.13 | |
| Allianz Asset Management Gmbh | $5.06M | 0.19 | 200,893 | +311.51% | +$3.83M | 0.01 | |
| AllianceBernstein | $5.02M | 0.19 | 199,354 | -18.46% | -$1.14M | <0.01 | |
| JPMorgan Chase | $4.88M | 0.19 | 193,571 | -3.01% | -$151,467.49 | <0.0001 |